Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer

NCT02470468 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Stage IV Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: DCVAC add on to SOC
BIOLOGICAL: DCVAC and immune enhancers add on to SOC
OTHER: Standard of Care Chemotherapy

Sponsor

SOTIO a.s.